A meta-analysis of uncontrolled observational studies of rituximab in patients with MG showed a trend toward an inverse correlation between the duration of disease and rate of response [ 42 ].
← all excerpts
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.
1
—
—